Trial Profile

A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABSK 112 (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Abbisko Therapeutics

Most Recent Events

17 Jan 2024 Status changed from not yet recruiting to recruiting.
07 Jul 2023 New trial record
04 Jul 2023 According to Abbisko Therapeutic media release, the company announced that IND has been approved by FDA for this phase I clinical trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com